Abstract
Human medicines European public assessment report (EPAR): Cinqaero, reslizumab, Asthma, Date of authorisation: 15/08/2016, Revision: 8, Status: Authorised
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have